BBI

Brickell Biotech Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8104
+0.0304
+3.90%
After Hours: 0.8250 +0.0146 +1.80% 19:58 09/25 EDT
OPEN
0.8600
PREV CLOSE
0.7800
HIGH
0.8750
LOW
0.8050
VOLUME
5.45M
TURNOVER
--
52 WEEK HIGH
4.290
52 WEEK LOW
0.7101
MARKET CAP
22.52M
P/E (TTM)
-0.2076
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Brickell/Kaken' sofpironium bromide gel Ok'd in Japan
Brickell Biotech (BBI) +8% in premarket, after its development partner, Kaken Pharmaceutical received approval to sofpironium bromide gel, 5% under the brand name ECCLOCK in Japan, for the treatment of primary axillary hyperhidrosis (abnormally excessive
Seekingalpha · 1d ago
Brickell Biotech Announces Approval Of Sofpironium Bromide Gel, 5% in Japan For Treatment Of Primary Axillary Hyperhidrosis Received By Its Development Partner, Kaken Pharmaceutical
Japan is the first country to approve sofpironium bromide with commercial launch expected later this year Brickell is on track to initiate its U.S. pivotal Phase 3
Benzinga · 1d ago
Brickell Biotech to Participate in September Virtual Investor Conferences
BOULDER, Colo., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that its management
GlobeNewswire · 09/10 21:05
AnGes, Brickell Biotech collaborate for COVID-19 DNA vaccine candidate
AnGes entered into a collaboration agreement with Brickell Biotech (BBI) +14% PM; under which the latter has the right to develop and commercialize the former's proprietary investigational adjuvanted plasmid DNA vaccine intended to
Seekingalpha · 09/08 12:50
AnGes and Brickell Biotech Announce a Collaboration Agreement for the Development of a Novel DNA Vaccine Candidate for COVID-19 in the U.S.
Advancement of the U.S. based program will be dependent upon results generated from AnGes’ ongoing and planned clinical studies in JapanIBARAKI CITY, Osaka and BOULDER, Colo., Sept. 08, 2020 (GLOBE NEWSWIRE) -- AnGes, Inc. (“AnGes”), announced today a collaboration agreement with Brickell Biotech, Inc
GlobeNewswire · 09/08 12:30
Anges, Brickell Biotech Announce Collaboration Agreement For Develop Of Novel DNA Vaccine Candidate For COVID-19 In U.S.
AnGes and Brickell Biotech Announce a Collaboration Agreement for the Development of a Novel DNA Vaccine Candidate for COVID-19 in the U.S. IBARAKI CITY, Osaka and BOULDER, Colo., Sept. 08, 2020 (GLOBE NEWSWIRE) --
Benzinga · 09/08 11:31
The Daily Biotech Pulse: Sanofi, Regeneron Drop COVID-19 Study, 2 Positive AstraZeneca Catalysts, Brickell Awarded Japanese Patent
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31)
Benzinga · 09/01 12:35
Brickell Biotech Announces Issuance of New Composition of Matter Patent on Sofpironium Bromide by the Japanese Patent Office
Claims directed to novel crystalline forms of sofpironium bromidePatent protection in Japan granted through 2040BOULDER, Colo., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated
GlobeNewswire · 08/31 21:05
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BBI. Analyze the recent business situations of Brickell Biotech Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BBI stock price target is 1.800 with a high estimate of 1.800 and a low estimate of 1.800.
EPS
Institutional Holdings
Institutions: 41
Institutional Holdings: 4.24M
% Owned: 15.25%
Shares Outstanding: 27.79M
TypeInstitutionsShares
Increased
5
361.03K
New
11
1.68M
Decreased
1
53
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Co-Founder/Director
Reginald Hardy
Chief Executive Officer/Director
Robert Brown
Co-Founder/Chief Operating Officer/Secretary
Andrew Sklawer
Chief Financial Officer
R. Carruthers
Chief Accounting Officer/Controller
Jose Breton
Chief Compliance Officer/General Counsel/Secretary
David McAvoy
Other
Deepak Chadha
Other
Adam Levy
Director
Gary Lyons
Director
Vijay Samant
Director
Dennison Veru
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BBI
Brickell Biotech, Inc., formerly Vical Incorporated, is a clinical-stage pharmaceutical company that focuses on the development of therapeutics for the treatment of skin diseases. The Company’s pipeline consists of molecular entities targeting the treatment of the indications, such as hyperhidrosis, cutaneous T-cell lymphoma, allergic contact dermatitis, psoriasis and androgenic alopecia. The Company’s product candidates include BBI-3000, BBI-6000 and Sofpironium Bromide. Sofpironium Bromide is a topical soft anticholinergic for axillary hyperhidrosis. BBI-3000 is an oral rexinoid for cutaneous T-cell lymphoma. BBI-6000 is a retinoic acid-related orphan nuclear receptor gamma antagonist, which is develops for psoriasis.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Brickell Biotech Inc stock information, including NASDAQ:BBI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BBI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BBI stock methods without spending real money on the virtual paper trading platform.